O'Rourke & Company’s Eli Lilly LLY Stock Holding History

O'Rourke & Company’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.31M	Sell	1,423 -2	-0.1%	-$2.03K	0.52%	50
2025 Q4	$1.53M	Buy	1,425 +6	+0.4%	+$5.74K	0.6%	40
2025 Q3	$1.08M	Sell	1,419 -95	-6%	-$70.7K	0.45%	50
2025 Q2	$1.18M	Sell	1,514 -48	-3%	-$37.3K	0.55%	45
2025 Q1	$1.29M	Buy	1,562 +83	+6%	+$69.1K	0.64%	35
2024 Q4	$1.14M	Buy	1,479 +27	+2%	+$22.4K	0.56%	39
2024 Q3	$1.29M	Buy	1,452 +340	+31%	+$306K	0.64%	36
2024 Q2	$1.01M	Buy	1,112 +29	+3%	+$23.2K	0.57%	39
2024 Q1	$843K	Buy	1,083 +256	+31%	+$182K	0.49%	48
2023 Q4	$482K	Buy	827 +340	+70%	+$198K	0.31%	65
2023 Q3	$262K	Hold	487	–	–	0.19%	107
2023 Q2	$228K	Buy	+487	New	+$204K	0.16%	125
2023 Q1	–	Sell	-787	Closed	-$288K	–	133
2022 Q4	$288K	Buy	+787	New	+$279K	0.23%	101

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $84.5B AUM 11.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

O'Rourke & Company's LLY Position: Q1 2026 in Review

O'Rourke & Company reduced its Eli Lilly (LLY) stake by 0.14% in Q1 2026, selling an estimated $2.03K and leaving 1,423 shares worth $1.31M. The position accounts for 0.52% of the portfolio, ranked #50.

O'Rourke & Company first reported a position in LLY in Q4 2022 and has held it in 13 quarters since. The position peaked at $1.53M in Q4 2025. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

O'Rourke & Company held 1,423 shares of Eli Lilly worth $1.31M as of Q1 2026.
O'Rourke & Company sold 2 Eli Lilly shares in Q1 2026, an estimated $2.03K.
Eli Lilly made up 0.52% of O'Rourke & Company's portfolio in Q1 2026, its #50 holding.
O'Rourke & Company first reported a position in Eli Lilly in Q4 2022 and has held it in 13 quarters since.
O'Rourke & Company's Eli Lilly position peaked at $1.53M in Q4 2025.
4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on O'Rourke & Company's 13F filing for Q1 2026, filed 14 May 2026.